Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D06GKN
|
||||
Former ID |
DAP000369
|
||||
Drug Name |
Alosetron
|
||||
Synonyms |
Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Gastrointestinal Agents
|
||||
Company |
Prometheus Laboratories Inc
|
||||
Structure |
Download2D MOL |
||||
Formula |
C17H18N4O
|
||||
InChI |
InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)
|
||||
InChIKey |
JSWZEAMFRNKZNL-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 122852-42-0
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
7348787, 8151424, 14922649, 29221279, 46506274, 50071299, 50112781, 51091468, 53789888, 57321137, 80814810, 85446390, 103306382, 103858511, 103926503, 104022587, 104299601, 126656041, 128322882, 131296577, 134337679, 135143907, 135649921, 137004775, 142472340, 152258886, 160647735, 160964307, 162176701, 164034868, 164814903, 175268748, 179116551, 184545919, 184675491, 185990404, 223391048, 224382917, 226393614, 250052138, 251888773, 252159855
|
||||
SuperDrug ATC ID |
A03AE01
|
||||
SuperDrug CAS ID |
cas=122852420
|
||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine receptor 3A | Target Info | Antagonist | [537217], [537382] | |
KEGG Pathway | Serotonergic synapse | ||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | 5HT3 type receptor mediated signaling pathway | ||||
Reactome | Ligand-gated ion channel transport | ||||
WikiPathways | SIDS Susceptibility Pathways | ||||
Iron uptake and transport | |||||
References | |||||
Ref 536224 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | ||||
Ref 539447 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2296). | ||||
Ref 537217 | Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta. 2009 May;403(1-2):47-55. Epub 2009 Feb 4. | ||||
Ref 537382 | Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844. Epub 2009 May 26. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.